midazolam has been researched along with ritonavir in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (34.15) | 29.6817 |
| 2010's | 24 (58.54) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Blanco, R; Coles, R; Kharasch, ED; Mitchell, D | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Gunaydin, H; Sun, Y; Weiss, MM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Greenblatt, DJ; Perloff, MD; Von Moltke, LL | 1 |
| Baxter-Meheux, F; Blake, MJ; Eron, JJ; Gaver, VE; Kashuba, AD; Klein, CE; Patterson, KB; Rezk, NL; Rublein, JC; Yeh, RF | 1 |
| Alfaro, RM; Davey, RT; Formentini, E; Penzak, SR; Robertson, SM; Voell, J | 1 |
| Greenblatt, DJ; Kaufman, RC; Knox, TA; Oleson, L; von Moltke, LL; Wanke, CA | 1 |
| Doroshyenko, O; Frank, D; Fuhr, U; Jetter, A; Lütjohann, D; Tomalik-Scharte, D | 1 |
| Acosta, EP; Fennerty, MB; Kubiak, DW | 1 |
| Hofmann, C; Patel, A; Riek, M; Schmitt, C; Zwanziger, E | 1 |
| Burhenne, J; Ding, R; Haefeli, WE; Hafner, V; Jäger, M; Matthée, AK; Mikus, G | 1 |
| Berkowitz, N; Court, MH; Greenblatt, DJ; Harmatz, JS; MacNab, MW; Oleson, LE; Peters, DE; Zinny, MA | 1 |
| Doroshyenko, O; Fätkenheuer, G; Frank, D; Fuhr, U; Hein, W; Jetter, A; Kirchheiner, J; Klaassen, T; Schömig, E; Seeringer, A; Wyen, C | 1 |
| Collier, AC; Kharasch, ED; Kirby, BJ; Thummel, KE; Unadkat, JD; Whittington, D | 1 |
| Burhenne, J; Haefeli, WE; Katzenmaier, S; Markert, C; Mikus, G; Riedel, KD | 1 |
| Ancrenaz, V; Daali, Y; Dayer, P; Déglon, J; Desmeules, J; Samer, C; Staub, C | 1 |
| Banba, H; Takayama, K; Takeda-Morishita, M; Tomaru, A | 1 |
| Ando, Y; Deguchi, M; Hirota, T; Ieiri, I; Irie, S; Izumi, N; Kanda, E; Kimura, M; Kotani, N; Kusuhara, H; Maeda, K; Matsuguma, K; Matsuki, S; Morishita, M; Okuzono, T; Sugiyama, Y; Tsunemitsu, S; Yamane, N | 1 |
| Aoyama, H; Fukushima, K; Kobuchi, S; Mizuhara, K; Sugioka, N; Takada, K | 1 |
| Blank, A; Burhenne, J; Cortese, M; Eichbaum, C; Mikus, G | 1 |
| Brennan, BJ; Chang, L; Giraudon, M; Kulkarni, R; Morcos, PN; Shulman, N; Smith, PF; Tran, JQ | 1 |
| Burhenne, J; Haefeli, WE; Lausecker, B; Mikus, G; Stoll, F; Thomsen, T; Weiss, J | 1 |
| Hee, KH; Lee, LS; Yao, Z | 1 |
| Greenblatt, DJ; Harmatz, JS | 1 |
| He, H; Heimbach, T; Huth, F; Umehara, KI; Won, CS | 1 |
| Adeloye, T; Dennison, J; Endo, T; Johnston, A; Puri, A; Sahgal, O; Warrington, S | 1 |
| Chakraborty, A; Dhuria, SV; Elmeliegy, M; He, H; Heimbach, T; Huth, F; Ji, Y; Miller, M; Samant, TS; Schiller, H; Umehara, K | 1 |
| Battegay, M; Marzolini, C; Sendi, P; Stader, F | 1 |
| Anderson, BJ; Hack, H; Svedmyr, A | 1 |
3 review(s) available for midazolam and ritonavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Topics: Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Drug Interactions; Humans; Ketoconazole; Midazolam; Ritonavir; United States; United States Food and Drug Administration | 2015 |
Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs.
Topics: Alfentanil; Anesthesia; Antiviral Agents; Child; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Inhibitors; Humans; Ketamine; Midazolam; Protease Inhibitors; Ritonavir; Rocuronium | 2022 |
15 trial(s) available for midazolam and ritonavir
| Article | Year |
|---|---|
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bupropion; Cross-Over Studies; Cytochrome P-450 CYP2B6; Female; HIV Protease Inhibitors; Humans; Liver; Male; Oxidoreductases, N-Demethylating; Ritonavir | 2008 |
Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Ginkgo biloba; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Phytotherapy; Plant Extracts; Protease Inhibitors; Pyrimidinones; Ritonavir; Terfenadine | 2008 |
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Topics: Administration, Oral; Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; GABA Modulators; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Injections, Intravenous; Male; Midazolam; Middle Aged; Ritonavir | 2008 |
Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Topics: Administration, Oral; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; HIV Protease Inhibitors; Humans; Hypericum; Infusions, Intravenous; Male; Midazolam; Plant Extracts; Ritonavir; Substance Withdrawal Syndrome; Young Adult | 2010 |
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Interactions; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Ritonavir; Young Adult | 2009 |
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
Topics: Administration, Oral; Adolescent; Adult; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Activation; Enzyme Induction; Female; HIV Protease Inhibitors; Humans; Injections, Intravenous; Intestines; Liver; Male; Midazolam; Middle Aged; Nelfinavir; Rifampin; Ritonavir; Substrate Specificity; Tissue Distribution; Young Adult | 2011 |
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Midazolam; Middle Aged; Pyrimidines; Ritonavir; Time Factors; Triazoles; Voriconazole; Young Adult | 2011 |
Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers.
Topics: Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Half-Life; HIV Protease Inhibitors; Humans; Male; Midazolam; Piperazines; Prasugrel Hydrochloride; Ritonavir; Thiophenes; Time Factors; Young Adult | 2013 |
Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Humans; Intestines; Liver; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Organic Anion Transporters; Pravastatin; Ritonavir; Saquinavir; Tandem Mass Spectrometry; Terfenadine; Young Adult | 2013 |
Concentration effect relationship of CYP3A inhibition by ritonavir in humans.
Topics: Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Female; HIV Protease Inhibitors; Humans; Male; Midazolam; Middle Aged; Nontherapeutic Human Experimentation; Ritonavir; Young Adult | 2013 |
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Topics: Adult; Antiviral Agents; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Midazolam; Middle Aged; Proline; Ritonavir; Sulfonamides; Vitamin K; Warfarin; Young Adult | 2013 |
Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Female; Humans; Male; Midazolam; Middle Aged; Ritonavir; Simvastatin | 2013 |
Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Calibration; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Freezing; Glucuronosyltransferase; Healthy Volunteers; Humans; Ketoconazole; Midazolam; Particle Size; Pyrrolidinones; Quality Control; Raltegravir Potassium; Reproducibility of Results; Rifampin; Ritonavir; Solid Phase Extraction; Tandem Mass Spectrometry; Xenobiotics | 2014 |
Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
Topics: Adolescent; Adult; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Oxadiazoles; Ritonavir; Young Adult | 2018 |
Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Biotransformation; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Midazolam; Models, Theoretical; Patient Safety; Purines; Rifampin; Risk Assessment; Ritonavir | 2020 |
23 other study(ies) available for midazolam and ritonavir
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
Topics: | 2013 |
Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Topics: Algorithms; Animals; Anti-Anxiety Agents; Antibodies, Blocking; Biotransformation; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; In Vitro Techniques; Intestinal Mucosa; Isoenzymes; Ketoconazole; Kinetics; Mice; Mice, Inbred ICR; Microsomes; Microsomes, Liver; Midazolam; Organ Specificity; Ritonavir; Troleandomycin | 2003 |
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Biomarkers; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Induction; Female; HIV Protease Inhibitors; HIV Seronegativity; Humans; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Lopinavir; Male; Midazolam; Middle Aged; Mixed Function Oxygenases; Omeprazole; Pyrimidinones; Ritonavir; Substrate Specificity; Warfarin | 2006 |
Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?
Topics: Administration, Oral; Adult; Benzilates; Cholesterol; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; HIV Protease Inhibitors; HIV Seropositivity; Humans; Hydroxycholesterols; Infusions, Intravenous; Lopinavir; Male; Midazolam; Middle Aged; Phenotype; Pyrimidinones; Ritonavir | 2009 |
Antiretroviral rounds. Happy 50th? Sedation for colonoscopy in HIV-infected patients.
Topics: Anti-HIV Agents; Colonoscopy; Conscious Sedation; Contraindications; HIV Infections; Humans; Hypnotics and Sedatives; Male; Midazolam; Middle Aged; Ritonavir | 2009 |
Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Topics: Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Female; Half-Life; HIV Protease Inhibitors; Humans; Hypnotics and Sedatives; Male; Midazolam; Prospective Studies; Ritonavir; Saquinavir | 2009 |
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Digoxin; Down-Regulation; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Middle Aged; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Analysis of the pharmacokinetic boosting effects of ritonavir on oral bioavailability of drugs in mice.
Topics: Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Protease Inhibitors; Inactivation, Metabolic; Mice; Microsomes; Midazolam; Pravastatin; Ritonavir; Saquinavir; Terfenadine | 2013 |
Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Midazolam; Rats; Rats, Wistar; Rhodamine 123; Ritonavir | 2013 |
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates.
Topics: Computer Simulation; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Humans; Midazolam; Models, Biological; Ritonavir | 2018 |
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
Topics: Adult; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytokine Release Syndrome; Cytokines; Humans; Lopinavir; Metabolic Clearance Rate; Midazolam; Middle Aged; Models, Biological; Ritonavir | 2022 |